Canntab Reaches Agreement with Innovative Bioinformatics Company, 36eight Technologies Inc.

CANNANNEW REPORT

Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has reached an agreement (the “Agreement“) with 36Eight Technologies Inc. (“36Eight“), a growing bioinformatics pharmacological healthcare data and technology company, which has developed  a proprietary artificial intelligence and machine learning algorithm which augments the  underlying clinical data/knowledge to efficiently understand a patient’s unique medical needs. 36Eight’s first-of-its-kind clinical intelligence software assists physicians, nurses, and pharmacists in screening for drug-cannabis interactions, and to optimize health outcomes via cannabis product dose combination, titration, and ongoing clinical assessment. 36Eight will list, market and support all of Canntab’s market-exclusive and patent-protected solid and exact dose products, which can be time released, extended released and ODT (oral dissolvable) in a variety of strengths and combinations, on its platform. “This is an exciting opportunity for Canntab, as we believe 36Eight’s unique and valuable complementary platform will support our ability to provide effective solutions for patients while reinforcing the confidence of patients in their relationship with their clinical pharmacist,” said Larry Latowsky, CEO of Canntab. “When I was CEO of Katz Group Rexall, I had the pleasure of working on many initiatives with John Tse, 36Eight’s founder and CEO, when he was London Drugs’ Vice President overseeing their pharmacy division. As a licensed pharmacist himself, Mr. Tse fully comprehends the importance that optimizing outcomes with medical cannabis products requires careful care management, which is exemplified by 36Eight’s intelligent dosage platform.” “Canntab’s product offerings are unlike any other product we support, as they are unique in that they provide exact dosage in a solid format, one that pharmacists and patients are comfortable with as a traditional delivery system,” said John Tse, 36Eight’s Founder and CEO. “We expect that with our…

Excerpt only …
READ MORE BELOW
Source : Canntab Reaches Agreement with Innovative Bioinformatics Company, 36eight Technologies Inc.

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.